- Home
- BMRC vs ETON Comparison
BMRC vs ETON Comparison
Compare BMRC & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | ETON |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.6M | 411.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMRC | ETON |
|---|---|---|
| Price | $27.24 | $17.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $28.00 | ★ $29.67 |
| AVG Volume (30 Days) | 103.6K | ★ 223.5K |
| Earning Date | 01-26-2026 | 03-17-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $33,022,000.00 | ★ $70,316,000.00 |
| Revenue This Year | $334.71 | $107.23 |
| Revenue Next Year | $6.44 | $29.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 102.77 |
| 52 Week Low | $19.14 | $11.09 |
| 52 Week High | $28.48 | $23.00 |
Technical Indicators
Market Signals| Indicator | BMRC | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 66.07 |
| Support Level | $26.76 | $14.49 |
| Resistance Level | $28.04 | $15.01 |
| Average True Range (ATR) | 0.87 | 0.68 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 55.07 | 83.33 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.